Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

VentriPoint Diagnostics Ltd V.VPT

Alternate Symbol(s):  VPTDF

Ventripoint Diagnostics Ltd. is a Canada-based medical device company. It is engaged in the development and commercialization of diagnostic tools to monitor patients with heart disease. It develops a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, technically difficult imaging and cardiotoxicity in oncology patients. It provides application of artificial intelligence to echocardiography. Its flagship product, Ventripoint Medical System (VMS+), enhances echocardiography to deliver cMRI levels of accuracy for volumetric measurements and ejection fractions for all four chambers of the heart. It has developed a solution that transforms cardiac care through its 3D ECHO and MRI software. VMS products are powered by its proprietary Knowledge Based Reconstruction technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI.


TSXV:VPT - Post by User

Comment by snuff133on Mar 09, 2021 9:00am
240 Views
Post# 32750927

RE:news

RE:newsAttached is a news release.  Here is some background:

1.      All medical devices have to be cleared, licensed, certified..lots of different “words” for regulatory approvals to sell the device in different countries.
2.      The company has these approvals in Canada, USA, Europe and China, but still needs to maintain a comprehensive Quality Assurance System (QAS), which is audited regularly. 
3.      In addition, we have established our own manufacturing facility for the VMS+3.0 and that too has been inspected every 3 months for a year to make sure it is being run in accordance with North American regulations.  Since we have passed all 4 inspections this year, we can go to less frequent inspections in the future.
4.      The regulations also evolve over so we must also change how we do things to remain compliant.
5.      It is a lot of paperwork and training of staff to remain in compliance with all the regulations, but it is necessary to maintain our approvals as well as to maintain the safety and quality of our products.   
6.      The recent QAS audit was a comprehensive one with a complete review of our technical file in Europe.  It took many months to complete, but it is now not needed again for some years.
7.      I have elected to tell you all about these successful audits so you will understand how hard the team is working and how successful it has been maintaining our status in spite of working from home and COVID limitations.

Thank you for your interest and support as we continue our mission to improve cardiac diagnostics and care world-wide for everyone and especially for children.

Regards,

Dr. George Adams ICD.D
Executive-Chairman
<< Previous
Bullboard Posts
Next >>

USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse